middle.news
Radiopharm Completes Phase 2b Trial with 90% MRI Concordance for RAD 101
8:50am on Thursday 16th of April, 2026 AEST
•
Healthcare
Read Story
Radiopharm Completes Phase 2b Trial with 90% MRI Concordance for RAD 101
8:50am on Thursday 16th of April, 2026 AEST
Key Points
Final patient dosed in U.S. Phase 2b RAD 101 imaging trial
Interim results show 90% concordance with MRI, primary endpoint
RAD 101 targets fatty acid synthase to improve brain metastases detection
Phase 3 pivotal trial planned with FDA engagement underway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE